2 recruiting, 1 active not recruiting, 1 withdrawn. 2 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Withdrawn 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Selective Estrogen Receptor Modulators: new trials by email Literature Review of Selective Estrogen Receptor Modulators trials Research Report on Selective Estrogen Receptor Modulators
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. Everolimus, Elacestrant, Placebo - Advanced Breast Cancer, ER-positive Breast Cancer | Phase 3 | Recruiting | MedSIR | 300 | 2024-12-05 | 2026-08-24 |
| Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor - Ductal Carcinoma in Situ | Phase 1 | Recruiting | Finn, Olivera, PhD | 50 | 2024-02-07 | 2026-10-16 |
| Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor + AI - Breast Cancer, ER-positive Breast Cancer | Phase 2 | Active not recruiting | University of Miami | 24 | 2023-06-12 | 2026-01-13 |
| Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer Sabizabulin, Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator - Metastatic Breast Cancer | Phase 2 | Withdrawn | Veru Inc. | 2023-03-15 | 2023-03-24 |
Breast Neoplasms (2) · Carcinoma, Intraductal, Noninfiltrating (1)
Finn, Olivera, PhD (1) · MedSIR (1) · University of Miami (1) · Veru Inc. (1)
United States (3) · Austria (1) · Brazil (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Italy (1) · Spain (1) · United Kingdom (1)
Antonio Llombart-Cussac, M.D., Ph.D. (1) · Emilia Diego, MD (1) · Frances Valdes-Albini, MD (1)